Jan Holmgren
Overview
Explore the profile of Jan Holmgren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
4039
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoque M, Kim D, Ahmmed F, Islam M, Im J, Tadesse B, et al.
Lancet Microbe
. 2025 Jan;
6(3):100981.
PMID: 39765235
Background: Patients with cholera have been shown to be protected against subsequent cholera for 3 years after their initial episode. We aimed to assess protection at 10 years of follow-up....
2.
Kantele A, Riekkinen M, Jokiranta T, Pakkanen S, Pietila J, Patjas A, et al.
J Travel Med
. 2023 Apr;
30(7).
PMID: 37099803
Background: No licensed human vaccines are available against enterotoxigenic Escherichia coli (ETEC), a major diarrhoeal pathogen affecting children in low- and middle-income countries and foreign travellers alike. ETVAX®, a multivalent...
3.
Terrinoni M, Nordqvist S, Lofstrand M, Nilsson F, Kallgard S, Sharma T, et al.
Vaccine
. 2023 Apr;
41(21):3347-3357.
PMID: 37085452
The feared diarrheal disease cholera remains an important global health problem. Use of oral cholera vaccine (OCV) from a global stockpile against both epidemic and endemic cholera is a cornerstone...
4.
Strober W, Holmgren J, Mowat A
Mucosal Immunol
. 2023 Jan;
16(1):1-2.
PMID: 36634818
No abstract available.
5.
Sen Chaudhuri A, Yeh Y, Zewdie O, Li N, Sun J, Jin T, et al.
Mucosal Immunol
. 2022 Jun;
15(5):1028-1039.
PMID: 35729204
The lack of clinically applicable mucosal adjuvants is a major hurdle in designing effective mucosal vaccines. We hereby report that the calcium-binding protein S100A4, which regulates a wide range of...
6.
Deen J, Holmgren J, Clemens J
Lancet Infect Dis
. 2022 May;
22(10):e292-e298.
PMID: 35533702
Cholera causes substantial morbidity and mortality in the world's poorest populations. For nearly a decade, an inactivated oral cholera vaccine (OCV) stockpile has been available to control and prevent outbreaks....
7.
Holmgren J
J Infect Dis
. 2021 Aug;
224(12 Suppl 2):S742-S748.
PMID: 34453544
The rapid spread of the seventh cholera pandemic over Asia in the 1960s led to several large field studies that revealed that the traditional injectable cholera vaccines had poor efficacy,...
8.
Chowdhury F, Ali Syed K, Akter A, Bhuiyan T, Tauheed I, Khaton F, et al.
Vaccine
. 2021 Jul;
39(32):4450-4457.
PMID: 34218960
Background: The World Health Organization (WHO) recommends the use of oral cholera vaccines (OCVs) as part of an integrated control program, both in highly endemic settings and during cholera epidemics....
9.
Holmgren J
Trop Med Infect Dis
. 2021 Apr;
6(2).
PMID: 33925118
Individual resistance to cholera infection and disease depends on both innate host factors and adaptive immunity acquired by a previous infection or vaccination. Locally produced, intestinal-mucosal secretory IgA (SIgA) antibodies...
10.
Mattisson I, Rattik S, Bjorkbacka H, Ljungcrantz I, Terrinoni M, Lebens M, et al.
Vascul Pharmacol
. 2021 Apr;
140:106863.
PMID: 33857652
Patients suffering from systemic lupus erythematosus (SLE) are at increased risk of developing cardiovascular disease (CVD) and traditional therapies including statins provide insufficient protection. Impaired removal of apoptotic material is...